Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV- 1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 5, 1999, Pages 453-460

  Seminari, Elena ^a   Maggiolo, Franco ^b   Villani, Paola ^c   Suter, Fredy ^b   Pan, Angelo ^d   Regazzi, Mario B ^c   Tinelli, Carmine ^e   Maserati, Renato ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c Cattedra di Tossicologia   (Italy)

^d CREMONA HOSPITAL   (Italy)

^e Direzione Scientifica   (Italy)

Author keywords

Efavirenz; HIV 1 infection; Nelfinavir; Rescue therapy; Stavudine

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RASH; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIRUS HEPATITIS; VIRUS LOAD; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033572275     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199912150-00005     Document Type: Article

References (41)

1. Carpenter CCJ, Fischl MA, Hammer S, et al. Antiretroviral therapy for HIV-1 infection in 1998. JAMA 1998;280:78-86.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-30.
4. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-91.
5. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997;349:1408-9.
6. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virologie treatment failure in a patient with HIV-1 starting a protease inhibitor. AIDS 1998;12:2161-7.
7. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virologie treatment failure of protease inhibitor therapy in an unselected cohort of HIV-1-infected patients. AIDS 1997;11:F113-6.
8. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentration and protease mutations in patients with advanced HIV-1 infection treated with ritonavir plus saquinavir. AIDS 1997;11:F95-9.
9. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologie failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
10. Vandamme AM, van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs. Drugs 1999;57:337-61.
11. Condra JH. Resisting resistance: maximizing the durability of antiretroviral therapy. Ann Intern Med 1998;128:951-4.
12. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologie response to salvage therapy. AIDS 1999; 13:F17-21.
13. Havlir D, Lange JMA. New antiretrovirals and new combinations. AIDS 1998;12(Suppl A):S165-74.
14. Wu EY, Wilkinson JM, Naret DG, et al. High-performance liquid chromatographic method for the determination of NFV, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Appl 1997;695:373-80.
15. Villani P, Pregnolato M, Banfo S, et al. High-performance liquid chromatographic method for analyzing the antiretroviral agent EFV in human plasma. Ther Drug Monitor 1999;21:346-50.
16. Merry C, Barry MG, MulCahy F, et al. The pharmacokinetics of combination therapy with NFV plus nevirapine. AIDS 1998; 1163-7.
17. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994;38:1428-32.
18. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998;42:2637-44.
19. Ruiz N, DuPont Merck Study Group. A double-blind pilot study to evaluate the antiretroviral activity and tolerability of DMP 266 in combination with indinavir (cohort III) [abstract LB-2]. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
20. Winslow DL, Garber S, Reid C, et al. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 1996;10:1205-9.
21. Riddler S, Kahn J, Hicks C, Havlir D, et al. Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for EFV (DMP 266) in combination with Indinavir (IDV) [DMP 266-003, Cohort IV]. [abstract 12359]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
22. Haas D, Hicks C, Seekins D, et al. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of EFV (DMP-266) in combination with open-label zidovudine (ZDV) with Lamivudine (3TC) at 24 weeks (DMP 266-005) [abstract 698]. Presented at the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1998.
23. Mildvan D, Martin G, Eyster M, et al. Initial effectiveness and tolerability of NFV (NFV) in combination with EFV (EFV, SUSTIVATM, DMP 266) in antiretroviral therapy naive or nucleoside analogue experienced HIV-1 infected patients: characterization in a phase II, open-label, multicenter study at 16 weeks [DMP 266-024] [abstract 22396]. Presented at the 12th World AIDS Conference, Geneva, Switzerland, 1998.
24. Perry CM, Benfield P. Nelfinavir. Drugs 1997;54:81-7.
25. Jarvis B, Faulds D. Nelfinavir. Drugs 1998;56:147-67.
26. Ballard C, Toerner JG, Colwell B, Mathews WC. Early CD4, viral load, and quality of life response to salvage treatment with NFV: the UCSD Owen Clinic NFV expanded access experience [abstract I-192]. Presented at the International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997.
27. Walmsley S, Walach C, Moses A, Salit I, Humar A, Fletcher D. Salvage therapy with a combination including nelfinavir in patients failing treatment including a protease inhibitor (PI) [abstract 12285]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
28. Tebas P, Patick AK, Kane EM, et al. Virologie responses to a ritonavir-saqunavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999;4;13:F23-8.
29. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998;42:2637-44.
30. Hammer S, Squires K, DeGruttola V, et al. Randomized trial of abacavir (ABC) and nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologie failure receiving indinavir (IDV) [abstract 490]. Presented at the 6th Conference on Retroviruses and Opportunistic Infection, Chicago, IL, 1999.
31. Griffith BP, Brett-Smith H, Kim G, et al. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis 1996;173:1252-5.
32. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to d4T after 2 years of monotherapy. AIDS 1997;11:696-7.
33. Molguin A, Dietrich U, Irmelmann A, Soriano V. Genotypic and phenotypic resistance to d4T (d4T) after long-term monotherapy [abstract 32285]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
34. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologie outcome. J Infect Dis 1999;179:1375-81.
35. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetic, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-45.
36. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996;5:1183-99.
37. Merry, C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-1-infected patients. AIDS 1997;11:F29-F33.
38. Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis 1998;177:1514-20.
39. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of NFV mesylate, an inhibitor of human immunodeficiency virus (HIV-1)-1 protease, to treat HIV-1 infection. J Infect Dis 1998; 177:1533-40.
40. Pedneault L, Elion R, Adler M, et al. Stavudine (d4T), didanosine (ddI) and nelfinavir combination therapy in HIV-1-infected subjects: antiviral effect and safety in an ongoing pilot study [abstract 241]. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
41. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999;13: F35-F43.